Rationale: Although a cardioprotective function of target of rapamycin (TOR) signaling inhibition has been suggested by pharmacological studies using rapamycin, genetic evidences are still lacking. We explored adult zebrafish as a novel vertebrate model for dissecting signaling pathways in cardiomyopathy.
B ecause of its advantageous embryology and unique genetic tools, zebrafish embryo has become a recognized vertebrate model for studying genetic aspects of human diseases. 1 However, many human diseases, such as cardiomyopathy and heart failure, are adult diseases with a progressive pathogenesis, which are difficult to be recapitulated in zebrafish embryos. To explore the potential of adult zebrafish for cardiomyopathy studies, we developed the first adult zebrafish model for cardiomyopathy induced by anemia. 2 We characterized pathogenesis in the heart of tr265, an anemic mutant incurred by a Band 3 mutation in erythrocytes that was identified from an ENU mutagenesis screen. 3 The chronic anemic stress to the heart induces profound cardiac enlargement, followed by cardiomyopa-thy-like phenotypes. 2 Because of the unique regeneration capacity of a zebrafish heart, both cardiomyocyte (CM) hypertrophy and hyperplasia contribute to the pathogenesis in the tr265 fish. To validate adult zebrafish as a conserved vertebrate model for cardiac diseases, its cardiac responses to other cardiomyopathy-inducing biomechanical stresses must be assessed.
In the present study, we report the second adult zebrafish model of cardiomyopathy induced by doxorubicin (DOX, adriamycin) . In contrast to the anemia model, we found that CM hyperplasia does not contribute to this type of cardiomyopathy. DOX is an anthracyclin drug that has been used in the treatment of a broad spectrum of cancers. However, overdose of DOX imposes toxicities on the heart, 4 which can be categorized into 2 different types. 5, 6 Acute cardiotoxicity occurs immediately after the administration of DOX, presenting as hypotension, transient cardiac rhythm disturbance, or reduced heart size. By contrast, chronic cardiotoxicity appears years or decades after patient exposure to DOX, typically presenting as an irreversible, cumulative, and dosedependent cardiomyopathy that finally leads to congestive heart failure. 5, 6 Mechanistically, it has been hypothesized that DOX-induced cardiotoxicity is mediated by activation of free radical-induced mitochondrial damage, which in turn imposes oxidative stress on the heart and triggers apoptotic CM death. 7, 8 One of the major goals of cardiomyopathy studies is to identify a common pathological signaling pathway that can be intervened to achieve therapeutic benefit. Target of rapamycin (TOR) pathway is one of the candidates that interprets a variety of inputs, including nutritional status, energy level, growth factors, as well as cellular stresses, and then coordinates the regulation of cell growth, cell proliferation, and cell death. 9 A cardioprotective function of TOR signaling inhibition has been suggested by pharmacological studies using rapamycin, a specific inhibitor of TOR. In mice, rapamycin prevents cardiac hypertrophy induced by aortic constriction, 10, 11 by thyroid hormone, 12 or in the LEOPARD syndrome. 13 In humans, the treatment of patients after cardiac transplantation with rapamycin significantly attenuates left ventricular hypertrophy. 14 However, this notion, based on pharmacological studies, has not been supported by direct genetic analysis of components in TOR signaling. 15 In this study, we first set up a DOX-induced cardiomyopathy model in adult zebrafish. We then sought to utilize the zebrafish target of rapamycin mutant (ztor), which we have isolated from an insertional mutagenesis screen, to elucidate functions of TOR signaling in both DOX and our previously established anemia-induced cardiomyopathy models. Our data uncovered dynamic activity of TOR signaling in pathogenesis of cardiomyopathies and provides the first genetic evidence to support that TOR signaling is a common pathological pathway that can be leveraged for therapeutic benefits for cardiomyopathies of different etiology.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
CM Dissociation and Primary CM Culture
CMs from dissected ventricles of Tg(cmlc2:nuDsRed) fish or tr265 fish were dissociated as described previously. 2 The newly dissociated CMs usually attached to the cell culture chamber within 1 hour, which allows us to capture images for CMs area measurement by outlining each individual CM using ImageJ software (NIH). 2 The CM identity was determined by either the nuDsRed reporter in the Tg(cmlc2:nuDsRed) transgenic fish, Mef2, or ␣-actinin antibody staining. Both rod-and round-shaped CM populations were noted during the primary CM culture. Twenty to 40 rod-shaped CMs were identified for size quantification.
Cardiac Functional Analysis in Adult Fish
For fraction shortening (FS) measurement, casper;Tg(cmlc2:nuDsRed) fish were anesthetized in 0.16 mg/mL tricaine for 2.5 minutes and placed ventral side up on a slotted sponge. Movies of beating hearts were recorded using a digital camera attached to a fluorescent Leica MZ FLI III microscope. Images from movies were then used to measure the axis length between the myocardial borders of the ventricles at diastole and systole, respectively (see Online Figure II ). The percent fraction shortening (FS%) was calculated using the formula FS%ϭ(length at diastoleϪlength at systole)/(length at diastole)ϫ100. The red blood cell flow rate was measured as described previously. 2 More than 6 fish were used for each experimental group.
Transposon-Mediated Insertional Mutagenesis Screen
The gene-breaking transposon P9 was generated by subcloning the SB-P6 GBT 16 into a nearly full-length Tol2 vector. 17 In-crosses were conducted for each founder fish family to identify families exhibiting embryonic lethal phenotypes; xu015 is 1 of the 41 embryonic-lethal mutants identified from this screen.
Statistics
All values are shown as meanϮstandard error (SEM, nՆ3 otherwise noted). Student t test was used for comparisons between 2 special groups, and ANOVA was used for assessment differences among 3 or more groups. Probability values for the analysis of survival rates were determined by log-rank test. A value of PϽ0.05 was considered significant.
Results

DOX Induces Progressive and Pathological Cardiomyopathy in Adult Zebrafish
To assess DOX-induced cardiac responses in adult zebrafish, we injected DOX intraperitoneally into casper fish, ages 2 months to 1 year. The casper fish was chosen because of its transparent body at adult stage that facilitates both DOX injection and cardiac function measurement. 18 On the basis of mice studies, 19, 20 we empirically determined the proper dose. Injection of 50 g/g body mass (gbm) DOX led to severe mortality, as well as significant loss of body and heart mass at 4 weeks after injection, although the heart surface area/ body weight index remained unchanged ( Figure 1A and 1B and Online Figure I dose without a detectable change in body shape or size. However, a significantly enlarged heart was detected at both 4 weeks and thereafter, such as 12 weeks after injection ( Figure 1A and 1B and Online Figure I ). To assess whether the enlarged heart is due to myocyte hypertrophy, we dissociated individual hearts and isolated single CMs, whose identity was indicated by either ␣-actinin or Mef2 antibody staining ( Figure 1C ). Average size of individual CMs was significantly enlarged ( Figure 1C and 1D). The width but not the length of individual CMs was increased ( Figure 1E and 1F), confirming a hypertrophic growth. Because of its small size, a beating zebrafish heart has been difficult to be documented by echocardiography-based imaging technology. 21 We developed an alternative approach by crossing the semitransparent casper with the Tg(cmlc2:nuDsRed) line, which fluorescently labels all CMs nuclei red. 22 The resulted casper; Tg(cmlc2:nuDsRed) fish line allows the documentation of a beating heart using a fluorescent microscope directly. The recorded movies were then used to calculate fraction shortening and heart rate (Online Figure II , A). We detected reduced fraction shortening starting at 4 weeks after injection ( Figure 1G ) but unchanged heart rate (Online Figure II , C). To validate the cardiac function study, we further quantified red blood cell (RBC) flow rate, an assay developed to reflect cardiac function indirectly. 2 We detected a reduction of RBC flow rate in the DOX-treated fish beginning at 4 weeks after injection (Online Figure II, B) .
We then examined hallmarks of pathological cardiomyopathy in the DOX-injected fish. Expression of the atrial natriuretic factor (anf), a fetal gene and molecular marker of CM hypertrophy, was significantly upregulated after DOX injection ( Figure 1H ). Muscular disarray and myofibril loss were detected at 12 weeks after DOX injection through either ␣-actinin antibody staining or transmission electronic microscopy ( Figure 1I and 1J). Together, these data suggest that DOX induces progressive and pathological cardiomyopathy in adult zebrafish. The progression from adaptation phase to decompensation phase occurs at around week 4 after injection, which continues to progress into more severe cardiomyopathy at later stages.
Dynamics of TOR Signaling During Pathogenesis of 2 Adult Zebrafish Models of Cardiomyopathy
To assess the role of TOR signaling in DOX-induced cardiac responses, we measured the level of pS6K, an essential downstream signaling axe of TOR. We did not detect significant changes of pS6K level at 3 days after DOX injection. In contrast, pS6K level was consistently higher than that in the control group at both weeks 4 and 12 after injection, whereas the total protein level of S6K remained unchanged ( Figure 2A ).
We also measured pS6K level in our previously established tr265 anemia model. Our previous studies of this model revealed CM hypertrophy at the 3-to 10-week-old tr265 fish. However, a small portion of the tr265 fish that survived to weeks 12 to 16 are characterized by heart enlargement consisting of increased number of CMs with smaller size. 2 Consistent to the notion that tr265 fish at week-6 and week-12 ages represent 2 types of cardiac enlargement with different cellular nature, we detected upregulated pS6K at week 6 but downregulated pS6K level at week 12 ( Figure 2B ). Together, our data suggested dynamic TOR activity along the pathogenesis of 2 cardiomyopathy models.
Temporal TOR Reduction Through Rapamycin Treatment Attenuates Cardiac Enlargement Induced by Either DOX or Anemia
Next, we assess the effect of rapamycin treatment on different models of cardiomyopathy. First, we found that rapamycin treatment can effectively reduce pS6K level in both the DOX and anemia models (Figure 2A and 2B). Second, we detected that 1-week rapamycin treatment effectively attenuated DOX-induced cardiac enlargement at both week 4 and week 12 after injection ( Figure 2C and 2D). Similarity, we also found that the heart enlargement was significantly attenuated by rapamycin treatment at both week 4 and week 7 but not week 12 tr265 fish ( Figure  2E ), whereas the rapamycin treatment itself does not affect the general fish growth (data not shown). This line of data supports the notion that cardiac enlargement at week 12 is due to a distinct molecular/cellular mechanism. To further validate this notion and to exclude the possibility that distinct effects of rapamycin are simply due to different ages of fish, we used another anemia model induced by phenylhydrazine (PHZ), a compound that can be used to induce anemia in adult fish at any age. 2 We first validate that a 3-week PHZ treatment induced heart enlargement in fish at both week 3 to 5 and week 10 to 12 time windows ( Figure 2F ). We further detected that 1-week rapamycin cotreatment effectively attenuated the PHZ-induced heart enlargement in both fish groups, without disturbing the body length ( Figure 2F and data not shown). This observation validated the notion that 11-to 12-week-old tr265 fish represents a unique pathological stage that is characterized by reduced CM size and reduced TOR signaling. Together, our data demonstrated a conserved function of rapamycin in attenuating cardiac enlargement in zebrafish models of cardiomyopathies, as has been previously shown in mammalian models and humans.
Sustained TOR Reduction Through ztor ؉/؊ Attenuates Cardiomyopathy Induced by Either Anemia or DOX
We have conducted an insertional mutagenic screen using P9, a Tol2-based transposon vector containing a gene-breaking cassette, and identified xu015, a recessive embryonic lethal zebrafish mutant (Online Figure III , A). 16 Through linkermediated PCR (LM-PCR), a P9 insertion was detected in the intron between exon 5 and exon 6 of the zebrafish target of rapamycin (ztor) gene ( Figure 3A ). The linkage between this P9 insertion and the xu015 mutant phenotypes was established by genotyping 20 xu015/xu015 embryos (LOD score Ͼ6, Online Figure III , B). It was predicted that the insertion of P9 into an intron would hijack the splicing machinery of the target gene and lead to generation of 2 end transcripts, an N-terminal cDNA consisting of the first 5 exons and a C-terminal cDNA that fused with the GFP in the Tol2 construct. 16 Indeed, both end products can be detected by reverse transcription polymerase chain reaction (Online Figure IIIC) . The mRNA level of ztor was reduced in xu015 mutant to around 11% of that in normal sibling ( Figure 3C) . The TOR protein level was also reduced, as well as the phosphorylation level of ribosomal S6K, whereas the total S6K level remained unchanged ( Figure 3D ). On the basis of the above evidence, we conclude that xu015 is a ztor hypomorphic zebrafish mutant. In the following text, we will refer to this homozygous mutant as ztor Ϫ/Ϫ and heterozygous mutant as ztor ϩ/Ϫ .
The ztor Ϫ/Ϫ embryos appeared normal until 6 days after (post) fertilization (dpf), when the larvae became less active and exhibited characteristic dark livers at 7 dpf ( Figure 3B ). Most of the embryos died at 10 dpf. The size of ztor Ϫ/Ϫ embryonic heart appeared smaller at diastole but not systole (Online Figure III, D) . Both significantly reduced CM proliferation and cell size was observed in the ztor Ϫ/Ϫ embryonic heart at 7 dpf, as revealed by immunostaining with antibodies against PCNA and ␤-catenin ( Figure 3E through 3H). However, the ztor ϩ/Ϫ fish exhibited no overt phenotype until at least 9 months of age, as evidenced by their normal body length and body weight (data not shown). The TOR protein level, however, is reduced by 35% in the ztor ϩ/Ϫ fish at 6 months old. Both pS6K phosphorylation level and pAKT(Ser473) are reduced ( Figure 3I ), indicating that both TORC1 and TORC2 are affected. Similar changes of TOR downstream branches were detected in fish treated with 0.2 mol/L rapamycin 12 hours daily for 7 consecutive days. However, fish treated with 0.4 mol/L rapamycin 4 hours daily for 7 consecutive days exhibits reduced pS6K but activated pAKT(ser473), which is consistent to the existence of a negative feedback regulation by TORC1 to PI3K-AKT signaling. 9 Consistent with the notion that 4E-BP1 is a negative downstream effector of TOR signaling, we detected upregulated p4E-BP1 level in adult ztor ϩ/Ϫ fish compared with that in wild-type fish ( Figure 3I ).
The generation of ztor ϩ/Ϫ fish provides an opportunity to study the long-term effect of TOR haploinsufficiency on adult fish models of cardiomyopathy. To assess effects of sustained TOR reduction on DOX-induced cardiomyopathy, we injected 20 g/gbm DOX into 2-month-old ztor ϩ/Ϫ fish. Compared with wild-type control, the recovery of myofibril organization was detected in ztor ϩ/Ϫ at late stages, which is characterized by more evenly distributed expression of ␣-actinin, improved lateral alignment, and organization of sarcomeres ( Figure 4A and 4B ). Both ventricular enlargement and fetal gene anf reactivation were significantly rescued at 8 weeks after injection ( Figure 4C and 4D) . The RBC flow rate, an indirect index of cardiac function, was better maintained in ztor ϩ/Ϫ fish at week 8 after DOX injection and thereafter ( Figure 4E ). However, it is worthy pointing out that although this indirect assay is useful when direct quantification of fractional shortening cannot be conducted in a nontransparent adult fish, it cannot replace fractional shortening studies to assess cardiac function. More importantly, the survival rate was significantly increased in ztor ϩ/Ϫ fish after DOX treatment compared with that in wild-type control fish ( Figure 4F ).
We also assessed the long-term effect of TOR haploinsufficiency on the anemia model by generating a tr265; ztor ϩ/Ϫ double mutant fish line. Similar to the DOX model, the enlarged heart size in tr265 was attenuated in the tr265; ztor ϩ/Ϫ double mutant fish, as quantified by the ratio of ventricular size to body length index at 4 weeks of age (Online Figure IV, A and IV, B ). In addition, an elevated RBC flow rate was observed, indicating an improved cardiac function (Online Figure IV, C) . We went on to examine other hallmarks of cardiomyopathy and found that the expression level of anf was significantly reduced in the tr265; ztor ϩ/Ϫ double mutant fish (Online Figure IV, D) , as well as reduced muscular disarray and myofibril loss (Online Figure IV , F through IV, I). Importantly, the survival rate was also significantly improved in the tr265; ztor ϩ/Ϫ double mutants than that in tr265 fish ( Figure 4G ). As a control, we detected no difference in the relative hemoglobin concentration at week 9 between tr265; ztor ϩ/Ϫ and tr265 fish (Online Figure IV, E ), suggesting that ztor haploinsufficiency did not restore hemoglobin level in anemic fish. Furthermore, we validated that ztor ϩ/Ϫ fish exhibited attenuated cardiac enlargement induced by PHZ (Online Figure VI , A through VI, C). Together, the above data demonstrated that the suppression of TOR signaling exerts cardioprotective effects in both zebrafish models of cardiomyopathies.
Functions of TOR Signaling Inhibition on CM Hypertrophy
To elucidate the cellular mechanisms for the cardioprotective functions of TOR signaling inhibition, we first assessed CM hypertrophy. We found that the CM enlargement induced by DOX injection in the wild-type fish was significantly attenuated in the ztor ϩ/Ϫ fish ( Figure 5A) . Similarly, the size of isolated CMs was reduced in tr265; ztor ϩ/Ϫ double mutants compared with that in the tr265 fish at 4 weeks old ( Figure 5B) .
To test the hypothesis that the anti-CM hypertrophy function of TOR signaling inhibition is due to its direct action on CMs, we exploited zebrafish primary CM culture system. Immediately after dissociation and culture, we noticed rodshaped cells whose geometry resembles typical CMs in mammals (Online Figure V, A) . These CMs usually attached to the cell culture chamber within 1 hour and changed their shape after 3 days in culture, appearing to be more spread out with multiple filopodia (for a similar observation, see Reference 23), 23 suggesting a dedifferentiation process of the CMs. The sarcomere structures can be detected by either differential interference contrast imaging or ␣-actinin staining (Online Figure V, A and V, B) . The averaged CM size remained mostly unchanged throughout the 7-day culture process, despite the change of cell shape (Online Figure V, C) . Treatment with DOX for 2 hours at day 1 induced enlargement of CMs at day 5 in a dose-dependent fashion (Online Figure VII, B) . This observation indicated that adult zebrafish CMs exhibit a conserved hypertrophic response in mammals. 24, 25 Consistent to our in vivo studies, cotreatment with rapamycin effectively attenuated CM hypertrophy induced by DOX in vitro ( Figure 5C and 5D ).
Functions of TOR Inhibition on Myocyte Proliferation
In addition to myocyte hypertrophy (increased cell size), a zebrafish heart may respond to extrinsic or intrinsic stresses by changing CM cell number through cell proliferation or cell death. 26 In the tr265 anemia model, we found that myocyte hyperplasia contributed to all stages of pathogenesis. 2 Therefore, we assessed myocyte proliferation in the DOX model through PCNA staining of sectioned ventricles. The identity of CMs was indicated by costaining with a Mef2 antibody. We found that the CM PCNA index remained unchanged at either 3 days or 4 weeks after DOX injection ( Figure 6A and 6C ). There is also no significant PCNA index change detected in the ztor ϩ/Ϫ fish injected with or without DOX ( Figure 6D) . Similarly, we found that the proliferation index in the DOX-induced cellular hypertrophy model, as represented by 5-bromo-2-deoxyuridine (BrdU) incorporation, also remains unchanged ( Figure 6B  and 6E ). Together, we conclude that in contrast to the tr265 model, myocyte hyperplasia does not contribute to the enlarged heart seen in the DOX model.
Consistent with an antiproliferation function of TOR signaling inhibition in cancer cells, such function has also been noted in zebrafish CMs. In the DOX model, we found that rapamycin treatment inhibits CM proliferation, either in the presence or absence of DOX ( Figure 6D and 6E) . Similarly in the tr265 anemia model of cardiomyopathy, increased proliferation was significantly attenuated by rapamycin treatment or in tr265; ztor ϩ/Ϫ fish ( Figure 6F and 6G) . The similar observation was also made in the anemic model induced by PHZ (Online Figure VI, D) . To validate that the antiproliferative function of TOR signaling inhibition is due to a direct action on CMs, we measured the BrdU index of CMs in vitro. Consistently, we found that BrdU index in CMs isolated from the tr265 fish were significantly reduced on rapamycin treatment (Figure 6E and 6H) . Of note, this antiproliferation function of rapamycin on CMs was also detected in wild-type siblings both in vivo and in vitro ( Figure 6D, 6E , 6G, and 6H).
Functions of TOR Inhibition on CM Apoptosis and Autophagy
Previous studies indicated that CM apoptosis contributes significantly to DOX induced cardiotoxicity 27, 28 but not to the tr265 model of cardiomyopathy induced by anemia. 2 Therefore, we focused on the DOX model and assessed the contribution of CM apoptosis during DOX-induced cardiomyopathy, as well as the effects of TOR signaling inhibition. We found out that apoptosis index was dramatically induced at 4 weeks but not 3 days after DOX injection (20 g/gbm) ( Figure 7A, 7C, and 7D ), suggesting its contribution to DOX-induced late-onset cardiomyopathy. In our in vitro CM culture system, we also observed a dosedependent enlargement of CM size as well as activated apoptosis and increased CM loss (Online Figure VII, A and VII, C). Reduction of TOR signaling through either ztor ϩ/Ϫ or 1-week rapamycin treatment effectively reduced the activated CM apoptosis in vivo ( Figure 7A , 7C, and 7D). Consistently, the apoptotic signal was also significantly attenuated after cotreatment with rapamycin in vitro ( Figure 7B and 7E ). Together, our data indicated an antiapoptotic function for TOR signaling inhibition.
Prompted by the implication of autophagy in cardiomyopathies and DOX-induced cardiotoxicity, 29 -31 we assessed functions of autophagy in DOX-induced cardiomyopathy model. In contrast to pS6K, which is positively regulated by TOR, autophagy is a cellular degradation pathway that is negatively regulated by TOR. Lc3 II (microtubule-associated protein light chain 3 form 2) and p62/SQSTEM1 are 2 molecular markers that have been widely used to assess autophagic flux. 32, 33 The levels of Lc3 II are proportional to the number of accumulated autophagic vacuoles, whereas the level of p62 protein, which is degraded by autophagy, is inversely related to autophagy activity. We detected activated autophagy at early stages after DOX injection but suppressed autophagy at later stages, as indicated by Western blot to reveal both the Lc3 II conversion and p62 degradation ( Figure 8A ). This observation was validated by quantifying Lc3 aggregation dots after injecting DOX into Tg(GFP-Lc3) transgenic fish (Figure 8B and 8C) . 32 Rapamycin treatment restored autophagy to a level that is comparable to that in wild-type at 12 weeks after injection ( Figure 8C ). Together, our data confirmed dynamic activity of autophagy at different stages of pathogenesis in DOX-induced cardiomyopathy, whereas depressed autophagy reflects the later decompensational hypertrophy stage. Therefore, we propose that the proautophagy function of TOR inhibition might also be accountable for its cardioprotective effects.
Distinct Functions of TOR Signaling Inhibition Between DOX-Induced Acute Cardiotoxicity and Late-Onset Cardiomyopathy
Our data in zebrafish suggest a beneficial effect of TOR inhibition/autophagy activation on DOX-induced cardiomyopathy. However, 2 recent studies in rodent models indicated either a detrimental effect of TOR inhibition or a protective effect of TOR activation on DOX-induced acute cardiotoxicity. 19, 29 Prompted by the observation that autophagy activity is opposite at early stages versus later stages after DOX injection, we hypothesized that these seemingly conflicting conclusions resulted from stage-dependent functions of TOR. To test this hypothesis, we assessed adult fish injected with a higher dose of DOX (50 g/gbm) to exaggerate its acute cardiotoxicity, which is characterized by reduced heart size and severe mortality. Similar to fish injected with a low dose of DOX (20 g/gbm), activated autophagy and unchanged p-S6K levels were detected in fish at 3 days after high-dose DOX injection. Cotreatment with rapamycin further enhanced the autophagy activity and abolished most of the p-S6K level in both groups but had no significant impact on the level of total S6K protein (Online Figure VIII, A) . Indeed, in addition to opposite autophagy activities, the following 2 observations further validate the stage-dependent functions of TOR signaling inhibition. First, in contrast to an antiapoptosis function during late-onset cardiomyopathy, rapamycin cotreatment increased the CM apoptosis index in high-dose DOX-induced acute cardiotoxicity (Online Figure VIII , C and VIII, D). Second, rather than a cardioprotective effect in fish cardiomyopathy models but similar to those in acute rodent cardiotoxicity models, cotreatment of rapamycin further exerted a deleterious effect on the high-dose DOX-induced acute cardiotoxicity in zebrafish, as indicated by further increased fish mortality (Online Figure VIIIB) . Together, our data strongly suggested that TOR signaling inhibition exerts opposite effects on DOX-induced acute cardiotoxicity and late-onset cardiomyopathy.
Discussion
DOX-Induced Cardiomyopathy Exhibits Different Pathogenesis From That of the Anemia Model
In the present study, we reported the second adult zebrafish model of cardiomyopathy that is induced by DOX. Cardiac enlargement occurs at 4 weeks after DOX injection, which further progressed to decompensational remodeling at later stages, exhibiting hallmarks of cardiomyopathy including activation of fetal gene expression, muscular disarray, and myofibril loss. The enlarged heart and CM hypertrophy is consistent to DOX responses reported in some in vivo rodent models and in vitro culture system 24, 25, 28, 34 but is different from other rodent models that report reduced cardiac mass, increased CM atrophy, and dilated cardiomyopathy. 19, 20 The discrepancy is probably caused by different doses and/or different treatment protocols of DOX stresses, partially due to different focus on either acute or chronic effects of DOX. 35 At the cellular level, pathogenesis in our DOX model is different from that in the anemia model. First, CM proliferation is not activated in the DOX model, whereas activated myocyte hyperplasia occurs at all stages of pathogenesis in the anemia model. Given the high regenerative capacity of a zebrafish heart, this was a surprising observation, suggesting that activated CM proliferation is not necessarily a default stress response in a zebrafish heart. Second, CM hypertrophy contributes to the enlarged heart in the DOX model at all stages, whereas CM hypertrophy can be only detected at early stages in the anemia model. 2 Third, significantly activated apoptosis was detected in CMs in the DOX model, which had also been reported in other animal models for DOX-induced cardiotoxicity. 27, 28 In contrast, oncosis is a more dominant cell death pathway of CMs in the anemic model. 2 It is conceivable that the distinct cellular changes in the DOX model versus the anemia model are due to different stresses imposed on the heart. Anemia mainly imposes extrinsic stresses on the heart because of the significantly increased demand from the body to compensate for the reduced red blood cell concentration. In addition, hypoxic conditions within the heart might also impose an intrinsic stress. In contrast, DOX inflicts intrinsic damage on CMs, probably as the result of its disruptive function in mitochondria and consequent activation of oxidative stress in CMs. 7, 8 The intrinsic nature of this stress is underscored by the observation that DOX induces cellular hypertrophy and apoptosis in cultured CMs.
TOR Signaling Inhibition Exerts Cardioprotective Effects on Cardiomyopathies
Taking advantage of the forward genetic screen in zebrafish, we identified ztor mutant. Further studies based on the ztor ϩ/Ϫ fish provided direct genetic evidences to support a cardioprotective function of TOR signaling reduction on cardiomyopathy. This effect has been observed in 2 types of cardiomyopathies in adult zebrafish of different etiology, prompting an exciting hypothesis that activated TOR signaling is a common pathological event during cardiomyopathy, which can be intervened for therapeutic benefits.
Our results validated the cardioprotective function of TOR signaling inhibition suggested by pharmacological studies in mice. 10, 11, 13 However, cardiac-specific knockout studies of Mtor and raptor in mouse reported an accelerated heart failure progression on pressure overload, 36, 37 suggesting important functions of TOR signaling in normal cardiac physiology and adaptive cardiac hypertrophy. An important difference between the present study and the mouse studies is the dose of the TOR signaling inhibition. In the mouse studies, Mtor signaling was ablated to such a low level that most mice die within 8 weeks. 36, 37 In contrast, TOR expression is only reduced to 65% at the protein level in ztor ϩ/Ϫ , which allows these fish to survive to adulthood without any noticeable phenotypes. This statement can be better appreciated in the context that extreme starvation will lead to animal death, whereas regulated caloric restriction protects heart and prolongs their lifespan. 38 Together, our results put forward an important concept, that is, it is critical to control the dose of TOR signaling inhibition to achieve therapeutic benefits for cardiomyopathies.
TOR has been found to be involved in 2 structurally and functionally distinct complexes. Whereas TORC1 contains mTOR, mLST8, and raptor and is sensitive to rapamycin, TORC2 contains mTOR, mLST8, rictor, mSIN1, and PRR5 and is insensitive to rapamycin. 39 -41 The downstream signaling pathways of the TORC1 complex have been found to regulate protein synthesis, autophagy, and transcription. In contrast, the downstream signaling pathways of the TORC2 complex are implicated in regulating actin cytoskeleton structure. 39 -41 As shown in Figure 3I , 1-week rapamycin treatment recapitulates the attenuated TORC1 signaling in ztor ϩ/Ϫ fish, but TORC2 signaling can be either activated or attenuated, depending on the treatment protocols. Nevertheless, both rapamycin treatment protocols effectively attenuate cardiac enlargement, suggesting that this antihypertrophy function is likely conveyed by the TORC1 rather than the TORC2 complex.
At the cellular level, our data revealed that the cardioprotective effect of TOR signaling inhibition is due to its antihypertrophy, antiapoptosis, and proautophagy functions. Although our data derived from primary CM culture support a cell-autonomous function of TOR signaling within CMs, it is important to point out that our present approach cannot exclude the possibility that TOR signaling exerts its functions through other cell types in the heart, such as endocardial cells and fibroblasts.
It is of particular interest to note that autophagy is suppressed at later cardiomyopathy stages of the DOX model. Recent studies suggested that the protective autophagy level is reduced at later stages of heart failure, whereas activated autophagy can exert cardioprotective role by eliminating damaged organelles and/or toxic proteins that contribute to the pathogenesis of cardiomyopathy. 30, 42 Therefore, it is tempting to propose that the cardioprotective effect of TOR signaling inhibition might be conveyed by the activated autophagy. Further investigation is warranted to test this hypothesis.
Dynamic Activities of TOR Along Pathogenesis of Cardiomyopathies
A unique feature of TOR signaling revealed is that its activity varies significantly at different stages of pathogenesis of cardiomyopathies. In the anemia model, TOR-pS6K signaling is activated concurrently with predominant CM hypertrophy at the early stages but suppressed at the later stages. In the DOX-induced models, TOR-autophagy signaling of TOR is oppositely regulated during initial acute phase and later cardiomyopathy phase. Furthermore, TOR signaling inhibition exerts opposite effects on DOXinduced acute cardiotoxicity and late onset cardiomyopathy. This stage-dependent effect of TOR signaling explains the seemingly conflicting conclusion on the beneficial effect of TOR activation on DOX-induced acute cardiotoxicity, as reported in murine models, 19, 29 and the cardioprotective effect of TOR signaling inhibition on cardiomyopathies. Our results underscore the concept that cardiomyopathy is a progressive disease. It is important to note that distinct signaling events and/or even opposite activities of the same signaling pathway might occur at different stages of pathogenesis.
Together, our data present adult zebrafish as a novel and conserved vertebrate model organism for eliciting molecular mechanism of cardiomyopathies. As exemplified by this study, novel discoveries on dose-and stage-dependent functions of TOR signaling in cardiomyopathies have been made, both of which will be instructive for designing proper therapeutic strategies for DOX-induced cardiomyopathies. Complementing to the existing rodent models, further investigation utilizing this emerging animal model promises to facilitate our understanding of human cardiomyopathies.
